

Syracuse Bio Campus
Your U.S.-Based Bioconjugation Partner

ADC Facility



Why choose a single-site mAb production & conjugation CDMO?



Antibody Manufacturing

- Commercial Manufacturing Capacity
5,000L x 8 Bioreactors
- Clinical Manufacturing Capacity
1,100L x 4 Bioreactors



ADC Facility

- Process Development
- Conjugation
- Quality Control



Why choose a single-site mAb production & conjugation CDMO?



Speed & Simplicity

No inter-site tech transfer,
enabling faster and more efficient execution



Quality & Compliance

One integrated quality system across
manufacturing and conjugation



Cost & Risk Reduction

Simplified supply chain with minimized
operational complexity

Inside our ADC Manufacturing Capabilities



High-Potency API Safety

Industry-standard containment (OEL target 10ng/m³) ensures safe handling of potent compounds



Quality & Compliance Excellence

Flexible production of up to 1kL for clinical and commercial ADC drug substance



Scalable cGMP Manufacturing

In-house QC, extended characterization, and regulatory expertise for global compliance

Our Services

End-to-End Conjugation Services

As seamless as **A**(ntibody), **B**(io), **C**(onjugate)

Process Development

Early-Stage

- Development & Optimization

Late-Stage


- Transfer & Optimization
- Performance Qualification
- Continued Process Verification

Bioconjugation

- Bioconjugation Development
- ADC Quality Assessment

Analytical Services

- Raw Material Testing
- ADC Quality Assessment
- IPC Testing: Conjugation
- IPC Testing: Purification



Various Conjugation Processes


Modalities



Fab



F(ab')₂



Bispecific Ab



scFv

Nanobody



Fc fusion protein

Conjugation Processes

Including:

- Antibody-Oligonucleotide Conjugate
- Immuno-Stimulant Antibody Conjugate
- Antibody-Fluorophore Conjugate
- Antibody-Chelator Conjugate
- Antibody-Glycan Conjugate
- Antibody-Chelator Conjugate
- Degradable Antibody Conjugate
- Antibody-Peptide Conjugate
- PEGylation-Based Conjugate

SoluFlex Link™

Developed with



Branched Solubilizing Linker

LOTTE Biologics is developing a novel linker with a high hydrophilic profile

Hydrophilic Linker is proven to have below advantages:

- Improved Solubility
- Increased PK / PD
- Enhanced in-vivo efficacy



Increased Therapeutic Index

